Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

doi:10.1200/JCO.2017.76.2294

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Apr 2018

Lin Jessica J, Zhu Viola W, Yoda Satoshi, Yeap Beow Y, Schrock Alexa B, Dagogo-Jack Ibiayi, Jessop Nicholas A, Jiang Ginger Y, Le Long P, Gowen Kyle, Stephens Philip J, Ross Jeffrey S, Ali Siraj M, Miller Vincent A, Johnson Melissa L, Lovly Christine M, Hata Aaron N, Gainor Justin F, Iafrate Anthony J, Shaw Alice T, Ou Sai-Hong Ignatius

Abstract excerpt

Purpose Advanced anaplastic lymphoma kinase ( ALK) fusion-positive non-small-cell lung cancers (NSCLCs) are effectively treated with ALK tyrosine kinase inhibitors (TKIs). However, clinical outcomes in these patients vary, and the benefit of TKIs is limited as a result of acquired resistance. Emerging data suggest that the ALK fusion variant may affect clinical outcome, but the molecular basis for this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Crizotinib

Share to Drug Resistance, Neoplasm

Share to Lung Neoplasms

Share to Oncogene Proteins, Fusion

Share to Protein Kinase Inhibitors

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 29373100
DOI: 10.1200/JCO.2017.76.2294
PMCID: PMC5903999

Genes

ALK
EML4

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.PMID 29373100Read ↗

The impact of the ALK fusion variant on clinical outcomes in EML4-ALK patients with NSCLC: a systematic review and meta-analysis.Semantic proximity Read ↗

Clinical consequences of resistance to ALK inhibitors in non-small cell lung cancer.Semantic proximity Read ↗

EML4-ALK fusion variant.3 and co-occurrent PIK3CA E542K mutation exhibiting primary resistance to three generations of ALK inhibitors.Semantic proximity Read ↗

EML4-ALK Variant 3a/b as a mechanism of osimertinib resistance in a patient with EGFR L858R positive NSCLC.Semantic proximity Read ↗

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.Semantic proximity Read ↗

EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveriesSemantic proximity Read ↗

Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations.Semantic proximity Read ↗

EML4-ALK: Update on ALK InhibitorsSemantic proximity Read ↗

Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database.Semantic proximity Read ↗

A comprehensive functional atlas of ALK kinase domain variants reveals resistance landscape to ALK inhibitors.Semantic proximity Read ↗

Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.Semantic proximity Read ↗

Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.